Clinical Trial

Efficacy and Safety of Add-on Timolol for EGFR-TKI and ALK-TKI Induced Paronychia

Recruiting Phase 3
View on ClinicalTrials.gov →
Record status
This record was last updated October 18, 2024 (before its estimated December 31, 2025 completion). Its status may not reflect the trial's current state.
Summary
To assess the clinical efficacy of add-on topical timolol 0.5% eye drops to betamethasone valerate 0.1% for the treatment of EGFR-TKI and ALK-TKI induced paronychia.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2024-10-14.
Trial Details
NCT Number NCT06643416
Lead Sponsor Queen Mary Hospital, Hong Kong
Conditions Paronychia, EGFR-TKI, ALK-TKI
Enrollment 40 participants
Start Date 2024-10-09
Primary Completion 2025-12-31 (estimated)
Study Completion 2025-12-31 (estimated)
Updated on ClinicalTrials.gov 2024-10-18